Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Dr Sekeres on the FDA Approval of Imetelstat in Lower-Risk MDS With Anemia

June 7th 2024

Mikkael A. Sekeres, MD, discusses the significance of the FDA approval of imetelstat for patients with lower-risk MDS and transfusion-dependent anemia.

FDA Approves Imetelstat for Low- to Intermediate-1–Risk MDS With Transfusion-Dependent Anemia

June 7th 2024

The FDA has approved imetelstat (Rytelo) for select patients with myelodysplastic syndrome and transfusion-dependent anemia.

Dr Kishtagari on JAK Inhibitor Selection for Myelofibrosis in the Community Setting

June 5th 2024

Ashwin Kishtagari, MD, discusses the selection process of JAK inhibitors for patients with myelofibrosis being treated in a community setting.

Updated MANIFEST-2 Data With Pelabresib/Ruxolitinib Support Paradigm Shift in Myelofibrosis

June 1st 2024

The addition of pelabresib and ruxolitinib (Jakafi) led to a significant and durable reduction in splenomegaly, among other improvements, vs ruxolitinib alone in JAK inhibitor–naive patients with myelofibrosis.

Dr Gerds on Updated Data for Pelabresib Plus Ruxolitinib in JAK Inhibitior–Naive Myelofibrosis

May 31st 2024

Aaron Gerds, MD, discusses updated efficacy and safety results for pelabresib and ruxolitinib in JAK inhibitor–naive myelofibrosis.

Recent Data Shed Further Light on the MDS Treatment Paradigm as the SOC Evolves

May 30th 2024

Jeremy Allred, MD, details current and emerging treatments for patients with myelodysplastic syndrome, highlighting recent key data updates.

JAK Inhibitor–Based Combinations Could Represent the Next Frontier in Myelofibrosis

May 22nd 2024

Ashwin Kishtagari, MD, discusses the investigation of JAK inhibitor–based combinations in myelofibrosis.

Navigating the Growing Landscape of JAK Inhibitors in Myelofibrosis

May 21st 2024

Ashwin Kishtagari, MD, discusses the treatment of patients with myelofibrosis following progression on ruxolitinib.

Dr Gangat on JAK Inhibitor Selection in Treatment-Naive Myelofibrosis

May 17th 2024

Naseema Gangat, MBBS discusses the clinical utility of momelotinib and JAK inhibitor selection in treatment-naive myelofibrosis.

Dr Kishtagari on the Impact of Momelotinib on the Management of Anemic Myelofibrosis

May 16th 2024

Ashwin Kishtagari, MD, discusses how momelotinib addresses unmet needs in the management of anemic myelofibrosis following disease progression on ruxolitinib.

Dr Ball on Data From from the IMerge Trial in Low– to Intermediate-Risk MDS

May 16th 2024

Somedeb Ball, MBBS, discusses data from the phase 3 IMerge trial of imetelstat vs placebo in low– to intermediate-risk myelodysplastic syndromes.

Novel Targets Beyond the JAK-STAT Pathway Aim to Push Myelofibrosis Treatment Forward

May 10th 2024

Anthony M. Hunter, MD, discusses the evolution of myelofibrosis treatment beyond JAK inhibitors.

Dr Klisovic on the Impact of Momelotinib on Myelofibrosis Management

May 9th 2024

Rebecca Klisovic, MD, discusses updates with JAK inhibitors, highlighting factors that inform JAK inhibitor selection in myelofibrosis.

Pooled Analysis Shows Cytoreduction to Be Safe, Tolerable in Younger Patients With PV

May 8th 2024

Cytoreductive therapy with rIFNα or hydroxyurea is safe and well tolerated in patients with polycythemia vera under the age of 60 years.

Dr Iyer on the Mechanism of Action of Imetelstat in Lower-Risk MDS

May 7th 2024

Sunil Iyer, MD, discusses the mechanism of action of imetelstat in patients with lower-risk myelodysplastic syndrome with anemia.

Dr Iyer on the Design of the COMMANDS Trial in Lower-Risk MDS With Anemia

May 1st 2024

Sunil Iyer, MD, discusses the design of the phase 3 COMMANDS trial in patients with lower-risk myelodysplastic syndrome with anemia.

Expansion of Luspatercept Indication Underscores Evolving Treatment Landscape for Low-Risk MDS

April 30th 2024

Benjamin Tomlinson, MD, discusses the first-line approval of luspatercept and other ongoing research in low-risk MDS.

Dr Jain on the VERONA Study in Higher-Risk MDS

April 30th 2024

Akriti Jain, MD, discusses the phase 1b VERONA study of venetoclax plus azacitidine in higher-risk myelodysplastic syndromes.

Dr Jurcic on the Use of JAK Inhibitors in Myelofibrosis Management

April 26th 2024

Joseph G. Jurcic, MD, discusses the use of JAK inhibitors in the management of myelofibrosis.

Dr Jain on Unmet Needs in the Treatment of Low- and High-Risk MDS

April 25th 2024

Akriti Jain, MD, discusses unmet needs in patients with low- and high-risk myelodysplastic syndromes.